Circumventing the action of NogoA with peptide antagonists, anti-NogoA antibodies, or soluble receptor fragments increases axon outgrowth and neural plasticity, resulting in improved functional recovery after stroke [4–7]. The gene discussed is RTN4; the disease is Stroke.